- Home
- XPON vs PHIO Comparison
XPON vs PHIO Comparison
Compare XPON & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPON
- PHIO
- Stock Information
- Founded
- XPON 2016
- PHIO 2011
- Country
- XPON United States
- PHIO United States
- Employees
- XPON 23
- PHIO N/A
- Industry
- XPON Electronic Components
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- XPON Technology
- PHIO Health Care
- Exchange
- XPON Nasdaq
- PHIO Nasdaq
- Market Cap
- XPON 2.3M
- PHIO 2.3M
- IPO Year
- XPON 2022
- PHIO N/A
- Fundamental
- Price
- XPON $2.45
- PHIO $2.47
- Analyst Decision
- XPON
- PHIO Strong Buy
- Analyst Count
- XPON 0
- PHIO 1
- Target Price
- XPON N/A
- PHIO $36.00
- AVG Volume (30 Days)
- XPON 566.8K
- PHIO 52.4K
- Earning Date
- XPON 11-14-2024
- PHIO 11-14-2024
- Dividend Yield
- XPON N/A
- PHIO N/A
- EPS Growth
- XPON N/A
- PHIO N/A
- EPS
- XPON N/A
- PHIO N/A
- Revenue
- XPON $4,498,181.00
- PHIO N/A
- Revenue This Year
- XPON $0.68
- PHIO N/A
- Revenue Next Year
- XPON $29.04
- PHIO N/A
- P/E Ratio
- XPON N/A
- PHIO N/A
- Revenue Growth
- XPON N/A
- PHIO N/A
- 52 Week Low
- XPON $2.09
- PHIO $2.17
- 52 Week High
- XPON $639.00
- PHIO $18.81
- Technical
- Relative Strength Index (RSI)
- XPON 34.81
- PHIO 42.71
- Support Level
- XPON $2.35
- PHIO $2.17
- Resistance Level
- XPON $2.83
- PHIO $2.66
- Average True Range (ATR)
- XPON 0.34
- PHIO 0.30
- MACD
- XPON 0.01
- PHIO -0.03
- Stochastic Oscillator
- XPON 11.33
- PHIO 19.71
About XPON Expion360 Inc.
Expion360 Inc is focused on the design, assembly, manufacturing and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles ("RV's") and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.